Aurinia Pharmaceuticals Inc. (AUPH): who owns it and who trades it
As of Nov 16, 2026, AUPH insiders reported 3 open-market sales worth $736K and 11 purchases worth $25.1M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Stephen P. Robertson (Chief Legal Officer), with $736K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Aurinia Pharmaceuticals
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AUPH
281 funds and institutions reported AUPH shares worth $1.3B at the end of Q2 2026, about 59% of the company. The largest holder is Tang Capital Management LLC with 9.8%.
Funds and institutions (13F) 59%Everyone else 41%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Tang Capital Management LLC | 13.04M | 9.81% | $221M | +7% |
| BlackRock, Inc. | 8.19M | 6.16% | $139M | +4% |
| Goldman Sachs Group Inc | 5.62M | 4.23% | $95.4M | +292% |
| NEA Management Company, LLC | 3.97M | 2.99% | $67.4M | No change |
| Two Sigma Investments, LP | 3.47M | 2.61% | $58.8M | +1% |
| Arrowstreet Capital, Limited Partnership | 3.26M | 2.45% | $55.4M | -1% |
| State Street Corp | 2.59M | 1.95% | $43.9M | +2% |
| Morgan Stanley | 2.31M | 1.74% | $39.2M | +3% |
| Marshall Wace, LLP | 2.04M | 1.54% | $34.7M | +9% |
| Geode Capital Management, LLC | 1.70M | 1.28% | $28.9M | +11% |
| Renaissance Technologies LLC | 1.55M | 1.16% | $26.3M | -7% |
| D. E. Shaw & Co., Inc. | 1.41M | 1.06% | $23.9M | -10% |
| Vanguard Portfolio Management LLC | 1.36M | 1.02% | $23.1M | +8% |
| Jacobs Levy Equity Management, Inc | 1.23M | 0.93% | $20.9M | +12% |
| Jupiter Asset Management Ltd | 1.09M | 0.82% | $18.6M | +36% |
| Lsv Asset Management | 1.08M | 0.81% | $18.3M | +4% |
| Nomura Holdings Inc | 978,602 | 0.74% | $16.6M | +1% |
| AQR Capital Management LLC | 948,751 | 0.71% | $16.1M | No change |
| Northern Trust Corp | 863,567 | 0.65% | $14.7M | +5% |
| Nuveen, LLC | 812,915 | 0.61% | $13.8M | +24% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AUPH insiders reported $25.1M of open-market purchases and $736K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Stephen P. Robertson | Chief Legal Officer | Sale | 11,867 | $15.97 | $190K | Form 4 |
| Sep 10, 2026 | Stephen P. Robertson | Chief Legal Officer | Sale | 11,939 | $15.95 | $190K | Form 4 |
| Aug 21, 2026 | Stephen P. Robertson | Chief Legal Officer | Sale | 20,975 | $16.97 | $356K | Form 4 |
| Jun 2, 2026 | Kevin Tang +1 | CEO | Purchase | 206,005 | $15.28 | $3.1M | Form 4 |
| Jun 1, 2026 | Kevin Tang +1 | CEO | Purchase | 343,521 | $15.28 | $5.2M | Form 4 |
| Jun 1, 2026 | Kevin Tang +1 | CEO | Purchase | 99 | $15.34 | $1.5K | Form 4 |
| May 29, 2026 | Kevin Tang +1 | CEO | Purchase | 2,299 | $15.35 | $35.3K | Form 4 |
| May 29, 2026 | Kevin Tang +1 | CEO | Purchase | 262,682 | $15.31 | $4M | Form 4 |
| Mar 3, 2026 | Kevin Tang | Director | Purchase | 184,208 | $14.22 | $2.6M | Form 4 |
| Mar 2, 2026 | Kevin Tang | Director | Purchase | 83,561 | $14.33 | $1.2M | Form 4 |
| Mar 2, 2026 | Kevin Tang | Director | Purchase | 115,792 | $14.21 | $1.6M | Form 4 |
| Feb 27, 2026 | Kevin Tang | Director | Purchase | 214,839 | $14.12 | $3M | Form 4 |
| Feb 27, 2026 | Kevin Tang | Director | Purchase | 1,600 | $14.38 | $23K | Form 4 |
| Feb 27, 2026 | Kevin Tang | Director | Purchase | 300,000 | $13.90 | $4.2M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kevin Tang | Director | $25.1M | – | Jun 2, 2026 |
| Stephen P. Robertson | Chief Legal Officer | – | $736K | Nov 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AUPH short interest
Moderate short interest. 5.3% of AUPH shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went down 21%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.14M AUPH shares were sold short, 5.3% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 692,192 shares, buying them all back would take about 10.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.14M | 5.33% | -8% | 692,192 | 10.3 |
| Oct 15, 2026 | 7.78M | 5.85% | -2% | 868,490 | 9.0 |
| Sep 30, 2026 | 7.92M | 5.95% | -8% | 844,517 | 9.4 |
| Sep 15, 2026 | 8.58M | 6.45% | -4% | 774,118 | 11.1 |
| Aug 31, 2026 | 8.98M | 6.75% | -7% | 1.05M | 8.6 |
| Aug 14, 2026 | 9.62M | 7.23% | +1% | 1.21M | 8.0 |
| Jul 31, 2026 | 9.53M | 7.16% | -2% | 1.01M | 9.4 |
| Jul 15, 2026 | 9.71M | 7.31% | +1% | 1.68M | 5.8 |
| Jun 30, 2026 | 9.59M | 7.21% | +4% | 2.47M | 3.9 |
| Jun 15, 2026 | 9.25M | 6.96% | +5% | 1.21M | 7.7 |
| May 29, 2026 | 8.82M | 6.63% | -2% | 1.12M | 7.9 |
| May 15, 2026 | 9.02M | 6.79% | +2% | 1.33M | 6.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Aurinia Pharmaceuticals company events
Aurinia Pharmaceuticals filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 30, 2026.
- Oct 30, 2026ResultsReleased financial results. Filing
- Aug 19, 2026AnnouncementAurinia Pharmaceuticals Inc. (Aurinia or the Company) issued a press release announcing that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation relating to… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 11, 2026DealAs previously disclosed by Aurinia Pharmaceuticals Inc. in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation, entered into an Agreement and Plan of Merger, dated as of March 30, 2026 by and among… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 3, 2026AgreementAurinia Pharma U.S., Inc., a Delaware corporation, entered into an Agreement and Plan of Merger by and among Kezar Life Sciences, Inc., a Delaware corporation, Parent, Aurinia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, and, solely for the purposes of Section… Filing
- Mar 23, 2026LeadershipDepartures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Aurinia Pharmaceuticals financials
Famous investors that hold AUPH
5 of the 50 well-known investors we track reported holding AUPH in their latest 13F filing. The largest position is Jim Simons's, worth $23.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.43M | $23.2M | 0.0% | -7% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 811,159 | $13.1M | 0.0% | +237% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 223,907 | $3.6M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 47,854 | $775K | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 16,895 | $274K | 0.0% | -93% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Aurinia Pharmaceuticals Inc. (AUPH) stock
Who owns the most AUPH stock?
The largest reported owner of Aurinia Pharmaceuticals Inc. (AUPH) is Tang Capital Management LLC, with 9.8% of the company. In total, 281 funds and institutions reported holding AUPH at the end of Q2 2026, together about 59% of the shares. See the largest owners.
Are AUPH insiders buying or selling?
In the last 12 months, AUPH insiders reported 11 open-market purchases worth $25.1M and 3 sales worth $736K. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in AUPH?
As of Oct 30, 2026, 7.14M AUPH shares were sold short, 5.3% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 692,192 shares, buying them all back would take about 10.3 trading days (days to cover). See the history.
Which famous investors hold AUPH?
5 of the 50 well-known investors we track reported AUPH in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $23.2M. See all holders.
Executive pay
Aurinia Pharmaceuticals's chief executive was paid a total of $5.9M for the year ended Dec 31, 2025, down 9% from $6.4M the year before. In the last 12 months, Aurinia Pharmaceuticals's executives and directors bought $25.1M of stock on the open market and sold $736K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.